{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-036302","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.733559+00:00","generated_at":"2026-06-20T23:59:46.450009+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Qualigen Therapeutics issues $3.3M 8% convertible debenture and warrant to Alpha Capital","bullets":["Issued $3.3M principal debenture for $3M purchase price; 8% interest starts Dec 2023, payable quarterly.","Conversion price $1.32/share; warrant for 2.5M shares at exercise price $1.65, exercisable from June 2023 to June 2028.","Proceeds to advance QN-302 IND candidate toward clinical trials and for working capital.","Monthly redemption of $110k+ interest begins June 2023, with optional redemption at 105% of principal.","Debenture and warrant unregistered, issued under Section 4(a)(2) exemption; registration rights agreement filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-036302","json":"https://secwatch.observer/filing/0001493152-22-036302.json","markdown":"https://secwatch.observer/filing/0001493152-22-036302.md","text":"https://secwatch.observer/filing/0001493152-22-036302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/0001493152-22-036302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:59:46.450009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"023bb58750a2fc60ee86e8ed5d87e94405d25cb7","claim":"AIxCrypto Holdings, Inc. incurred convertible notes of $3,300,000 with Alpha Capital Anstalt at 8% per annum maturing December 22, 2025.","evidence_excerpt":"Alpha Capital Anstalt (“Alpha”), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the “Debenture”) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000. The Debenture will be convertible, at any time, and from time to time, at Alpha’s option, into shares of common stock of the Company (the","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/0001493152-22-036302-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$3,300,000"},{"label":"Counterparty","value":"Alpha Capital Anstalt"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"December 22, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"cb5c3f3eeff4b1844769828922429ee30470ec90","claim":"AIxCrypto Holdings, Inc. entered into Securities Purchase Agreement with Alpha Capital Anstalt valued at $3,300,000 (effective 2022-12-21).","evidence_excerpt":"On December 21, 2022, Qualigen Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“Agreement”) with Alpha Capital Anstalt (“Alpha”), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the “Debenture”) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/0001493152-22-036302-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Alpha Capital Anstalt"},{"label":"Value","value":"$3,300,000"},{"label":"Effective","value":"2022-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}